Related Experiment Video
Updated: Jun 26, 2025
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
In silico identification of a novel Cdc2-like kinase 2 (CLK2) inhibitor in triple negative breast cancer
Cheng-Chiao Huang1,2,3, Chia-Ming Hsu3, Min-Wu Chao4,5,6
1Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan.
Abstract:
Dysregulation of RNA splicing processes is intricately linked to tumorigenesis in various cancers, especially breast cancer. Cdc2-like kinase 2 (CLK2), an oncogenic RNA-splicing kinase pivotal in breast cancer, plays a significant role, particularly in the context of triple-negative breast cancer (TNBC), a subtype marked by substantial medical challenges due to its low survival rates. In this study, we employed a structure-based virtual screening (SBVS) method to identify potential CLK2 inhibitors with novel chemical structures for treating TNBC. Compound 670551 emerged as a novel CLK2 inhibitor with a 50% inhibitory concentration (IC50) value of 619.7 nM. Importantly, Compound 670551 exhibited high selectivity for CLK2 over other protein kinases. Functionally, this compound significantly reduced the survival and proliferation of TNBC cells. Results from a cell-based assay demonstrated that this inhibitor led to a decrease in RNA splicing proteins, such as SRSF4 and SRSF6, resulting in cell apoptosis. In summary, we identified a novel CLK2 inhibitor as a promising potential treatment for TNBC therapy.
Insights
Researchers identified a novel inhibitor targeting Cdc2-like kinase 2 (CLK2) to treat triple-negative breast cancer (TNBC). This compound effectively reduced TNBC cell survival and promoted apoptosis, offering a promising new therapeutic avenue.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- RNA splicing dysregulation is linked to cancer development, particularly in breast cancer.
- Cdc2-like kinase 2 (CLK2) is an oncogenic kinase crucial in triple-negative breast cancer (TNBC) progression.
- TNBC presents significant treatment challenges due to poor survival rates.
Purpose of the Study:
- To identify novel chemical inhibitors of CLK2 for TNBC treatment using structure-based virtual screening.
- To evaluate the efficacy and selectivity of identified CLK2 inhibitors.
- To investigate the mechanism of action of promising CLK2 inhibitors in TNBC cells.
Main Methods:
- Structure-based virtual screening (SBVS) was employed to identify potential CLK2 inhibitors.
- Compound 670551 was identified and characterized for its inhibitory activity (IC50) and selectivity against CLK2.
- Cell-based assays were used to assess the compound's effects on TNBC cell survival, proliferation, RNA splicing proteins, and apoptosis.
Main Results:
- Compound 670551 was identified as a novel CLK2 inhibitor with an IC50 of 619.7 nM.
- The compound demonstrated high selectivity for CLK2 over other kinases.
- Compound 670551 significantly inhibited TNBC cell survival and proliferation, induced apoptosis, and decreased levels of RNA splicing proteins (SRSF4, SRSF6).
Conclusions:
- A novel CLK2 inhibitor, Compound 670551, was discovered.
- This inhibitor shows potential as a therapeutic agent for triple-negative breast cancer.
- The findings suggest CLK2 inhibition is a viable strategy for TNBC treatment.
